Back

Oral PCSK9 inhibitors as an emerging frontier in lipid management: a meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Changing face of lipid-lowering therapy Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Vinh Quang Tri Ho

Debrecen (Hungary)

5 More presentations in this session

Presentation thumbnail
Temporal trends in lipid-lowering therapy utilization among ASCVD patients: a large-scale database analysis
Doctor M. Goldberg (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Predictors of lipid-lowering therapy intensification over 1 year of prospective follow-up in Europe: insights from the SANTORINI study
Doctor C. Aguiar (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Real-world prescribing patterns for lipid-lowering therapy in high cardiovascular risk patients in germany: a cross-sectional analysis
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Efficacy of obicetrapib across the spectrum of background lipid lowering therapies-pooled analyses of the Broadway and Brooklyn randomised trials
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
Statin adherence in primary care among patients with hypertension with and without other cardiometabolic diseases
Doctor J. Sandslatt (Gothenburg, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Changing face of lipid-lowering therapy
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
thumbnail
Congress Presentation
What’s new on lipid-lowering drugs: from statins to gene editing and beyond
thumbnail
Congress Presentation
Resistance to lipid-lowering therapy with PCSK9 inhibitors: comparative efficacy and clinical implications

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources